technetium tc-99m labeled carbon: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335	NDA	Cyclomedica Australia Pty Limited	73814-987-20	1 KIT in 1 CARTON (73814-987-20) * 50 AEROSOL in 1 CARTON (73814-986-20) * 1 in 1 CARTON (GS1:19340598000050)	2023-09-29
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335	NDA	Cyclomedica Australia Pty Limited	73814-989-20	1 KIT in 1 CARTON (73814-989-20) * 50 in 1 CARTON (GS1:19340598000036) * 50 AEROSOL in 1 CARTON (73814-986-20)	2023-09-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis examines the supply chain for Technetium Tc-99m labeled carbon compounds, focusing on key suppliers, manufacturing processes, regulatory considerations, and market dynamics. The availability and reliability of Technetium Tc-99m (Tc-99m) are critical due to its widespread use in diagnostic imaging. The carbon labeling adds complexity, requiring specialized synthetic capabilities.

What are the primary applications of Technetium Tc-99m labeled carbon compounds?

Technetium Tc-99m labeled carbon compounds are primarily utilized in radiopharmaceutical development and biomedical research. Their utility stems from the short half-life and gamma-emitting properties of Tc-99m, making it suitable for in vivo imaging with minimal patient radiation exposure. Carbon-14 (¹⁴C) is a common isotope used for labeling, allowing researchers to track the metabolic fate, distribution, and excretion of a drug candidate or molecule within biological systems.

Drug Metabolism and Pharmacokinetics (DMPK) studies: Tc-99m labeled compounds allow for real-time tracking of drug absorption, distribution, metabolism, and excretion (ADME) in preclinical and, in some specialized cases, clinical settings. This is crucial for understanding how a drug behaves in the body and for determining optimal dosing regimens.
Target engagement studies: Researchers use these compounds to visualize and quantify the binding of a drug to its intended biological target, such as receptors or enzymes, in vivo.
Preclinical imaging: Tc-99m labeled carbon molecules can be employed in small animal imaging studies to assess biodistribution and target localization prior to human trials.
Development of novel radiotracers: The synthesis of Tc-99m labeled carbon compounds forms the basis for developing new diagnostic imaging agents tailored for specific diseases or biological processes.

Who are the key suppliers of Technetium Tc-99m labeled carbon compounds?

The supply chain for Tc-99m labeled carbon compounds is bifurcated. The first component involves the isotope production and supply of Tc-99m generators, which is a mature but sensitive global market. The second component involves specialized radiopharmaceutical manufacturers and custom synthesis providers who perform the labeling with carbon-containing molecules.

Tc-99m Generators and Precursors

The primary source of Tc-99m is the decay of Molybdenum-99 (⁹⁹Mo). ⁹⁹Mo is produced in nuclear reactors and then processed into a ⁹⁹Mo/⁹⁹mTc radioisotope generator.

Global ⁹⁹Mo Production: Historically, a limited number of facilities worldwide have been responsible for the bulk of ⁹⁹Mo production. Major producers include:
- Nordion (Canada): Operates the National Research Universal (NRU) reactor, a significant global supplier.
- Radioisotope Production Centre, Institute for Radioisotopes (IPI) (Hungary): Associated with the Csilla Máté Institute of Isotopes.
- Australian Nuclear Science and Technology Organisation (ANSTO) (Australia): Operates the Open-Pool Australian Lightwater (OPAL) reactor.
- Various other national facilities with varying production capacities.
Generator Manufacturers: These entities take purified ⁹⁹Mo and package it into sterile elution kits (generators) for use by hospitals and radiopharmacies. Examples include:
- GE Healthcare: A major global supplier of ⁹⁹mTc generators.
- Mallinckrodt Pharmaceuticals (formerly Covidien): Another significant player in the radiopharmaceutical market.
- Curium Pharma: A company active in nuclear medicine.

Specialized Radiopharmaceutical and Custom Synthesis Companies

These companies possess the expertise in organic synthesis and radiochemistry to attach the Tc-99m to carbon-based molecules. The "carbon" aspect typically refers to the organic scaffold of the molecule being radiolabeled.

Custom Synthesis and Contract Research Organizations (CROs): Many CROs specializing in radiochemistry offer custom synthesis of Tc-99m labeled compounds. These are not typically catalog products but are made to order for specific research projects. Examples of companies with radiolabeling capabilities include:
- RayBiotech, Inc.: Offers custom radiolabeling services.
- ABX GmbH: Known for its expertise in radiopharmaceuticals and preclinical services.
- ITM Isotope Technologies Munich SE: A leading supplier of radioisotopes and radiopharmaceuticals.
- PETNET Solutions (a Siemens Healthineers company): Provides radiopharmaceutical manufacturing and distribution, including custom synthesis.
Radiopharmaceutical Manufacturers: Larger pharmaceutical companies with dedicated nuclear medicine divisions may also produce specific Tc-99m labeled agents or offer custom labeling.

The exact suppliers for specific "Technetium Tc-99m labeled carbon" compounds depend on the exact chemical structure being synthesized. Often, researchers will order a carbon-based precursor molecule and then have it radiolabeled by a specialized radiopharmacy or CRO.

What are the manufacturing processes for Tc-99m labeled carbon compounds?

The manufacturing process involves two distinct phases: the production of Tc-99m and its subsequent radiolabeling onto a carbon-containing molecule.

Phase 1: Production of Technetium Tc-99m

Neutron Activation/Fission: Molybdenum-98 (⁹⁸Mo) is irradiated with neutrons in a nuclear reactor to produce Molybdenum-99 (⁹⁹Mo). Alternatively, ⁹⁹Mo can be obtained as a fission product from the irradiation of highly enriched uranium.
Separation and Purification: The ⁹⁹Mo is separated from other fission products and purified.
Generator Preparation: Purified ⁹⁹Mo is adsorbed onto an alumina column. This column is then enclosed in a sterile lead-shielded device, forming a ⁹⁹Mo/⁹⁹mTc radioisotope generator. The generator is shipped to end-users.
Elution: At the end-user facility (e.g., hospital radiopharmacy), a sterile saline solution is passed through the alumina column. This process selectively elutes the Technetium Tc-99m (⁹⁹mTc) from the ⁹⁹Mo, yielding a solution of sodium pertechnetate ([⁹⁹mTc]TcO₄⁻). ⁹⁹Mo has a half-life of 66 hours, while ⁹⁹mTc has a half-life of 6 hours, allowing for daily elution and use.

Phase 2: Radiolabeling with Carbon-Containing Molecules

This phase involves attaching the eluted [⁹⁹mTc]TcO₄⁻ to a specific organic molecule containing carbon atoms. This is a complex process requiring sterile conditions, radiochemical expertise, and specialized equipment.

Precursor Synthesis: A specific carbon-containing molecule (the "cold ligand" or precursor) is synthesized. This molecule must have a functional group that can chelate or bind to Tc-99m. Common chelating agents include hydrazines, thiols, and phosphines. The carbon backbone of this precursor molecule is what gives the final radiopharmaceutical its target specificity.
Radiolabeling Reaction: The eluted [⁹⁹mTc]TcO₄⁻ is mixed with the precursor molecule in the presence of a reducing agent (e.g., stannous chloride) and a buffer solution. The reducing agent is necessary to convert Tc(VII) in pertechnetate to a lower oxidation state that can coordinate with the ligand.
Incubation: The mixture is incubated under controlled conditions (temperature, time) to allow the radiolabeling reaction to proceed efficiently.
Purification: The resulting radiolabeled compound is purified to remove unreacted [⁹⁹mTc]TcO₄⁻, reducing agents, and byproducts. Common purification techniques include High-Performance Liquid Chromatography (HPLC) and solid-phase extraction (SPE).
Quality Control: Rigorous quality control tests are performed to ensure the radiochemical purity, radiochemical yield, sterility, and absence of pyrogens in the final product. This includes measuring specific activity, identifying impurities, and confirming that the radiolabel is correctly incorporated into the target molecule.
Formulation and Packaging: The purified radiopharmaceutical is formulated into a stable injectable solution and packaged into sterile vials for distribution.

The specific carbon components are inherent to the organic precursor molecule. For example, if a radiopharmaceutical targets a specific protein, the carbon backbone would be part of a small molecule designed to bind to that protein. The carbon atoms themselves are not typically isotopically labeled with ¹³C or ¹⁴C unless the study specifically requires isotopic tracing of the ligand itself, which is a separate process from Tc-99m labeling. However, the term "labeled carbon" in this context almost invariably refers to the carbon atoms within the organic molecule that Tc-99m is attached to.

What are the regulatory requirements for Tc-99m labeled compounds?

The manufacturing, distribution, and use of Tc-99m labeled compounds are subject to stringent regulations by national and international health authorities due to their radioactive nature and intended use in human or animal subjects.

Good Manufacturing Practices (GMP): Manufacturers of radiopharmaceuticals must adhere to GMP guidelines. This ensures that products are consistently produced and controlled according to quality standards appropriate for their intended use. For Tc-99m labeled compounds, this includes:
- Sterility and Aseptic Processing: Critical for injectable radiopharmaceuticals.
- Radiochemical Purity: Ensuring the radioactivity is predominantly in the desired chemical form.
- Radionuclidic Purity: Minimizing contamination by other radioisotopes.
- Control of Impurities: Including chemical impurities and pyrogens.
Radioisotope Handling and Licensing: Facilities that produce, possess, or use radioactive materials like Tc-99m must be licensed by national regulatory bodies. In the U.S., this is the Nuclear Regulatory Commission (NRC) or Agreement States. Similar authorities exist globally (e.g., the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA)).
Drug Master Files (DMFs): For proprietary precursors or manufacturing processes, companies may submit DMFs to regulatory agencies, providing detailed confidential information about the manufacturing, processing, packaging, and storing of the drug substance.
Investigational New Drug (IND) Applications: For new Tc-99m labeled compounds intended for clinical trials, an IND application must be submitted to regulatory authorities, outlining preclinical data, manufacturing information, and the proposed clinical trial protocol.
Abbreviated New Drug Applications (ANDAs) and New Drug Applications (NDAs): For commercially approved radiopharmaceuticals, full NDAs or ANDAs (for generics) are required, demonstrating safety and efficacy.
Transportation Regulations: The transport of radioactive materials, including Tc-99m generators and radiopharmaceuticals, is governed by strict international and national regulations (e.g., International Atomic Energy Agency (IAEA) regulations, Department of Transportation (DOT) in the U.S.) concerning packaging, labeling, and shipping documentation.
Radiation Safety: End-users (hospitals, research institutions) must implement comprehensive radiation safety programs, including personnel dosimetry, shielding, waste disposal protocols, and emergency preparedness.

What are the market dynamics and challenges for Tc-99m labeled carbon compounds?

The market for Tc-99m labeled carbon compounds is driven by the demand for diagnostic imaging and radiopharmaceutical research. However, it faces several unique dynamics and challenges.

Market Drivers

Aging Population: Increasing prevalence of age-related diseases such as cardiovascular disease, cancer, and neurological disorders drives demand for diagnostic imaging.
Advancements in Radiochemistry: Development of new Tc-99m labeled agents targeting specific biological pathways or diseases.
Growth in Nuclear Medicine: Expansion of nuclear medicine departments and increased adoption of SPECT imaging.
Preclinical Research Demand: Continuous need for radiolabeled molecules in drug discovery and development.

Key Challenges

Tc-99m Supply Vulnerability: The global supply of Tc-99m is critically dependent on a small number of aging nuclear reactors and processing facilities. Any disruption, such as unplanned outages or maintenance of these reactors, can lead to global shortages and price volatility. For example, the extended shutdown of Canada's NRU reactor in the late 2000s and early 2010s caused significant supply disruptions.
Short Half-Life: The 6-hour half-life of Tc-99m necessitates on-demand production and rapid delivery, complicating logistics and global distribution. This limits the geographic reach of suppliers and requires robust supply chain management.
Complexity of Custom Synthesis: The synthesis of specific Tc-99m labeled carbon compounds is often a custom process, requiring specialized expertise, equipment, and stringent quality control. This can lead to longer lead times and higher costs for tailored radiotracers.
Regulatory Hurdles: The extensive regulatory requirements for radiopharmaceutical manufacturing and distribution can be a significant barrier to entry and add considerable time and cost to product development.
Competition from Other Isotopes: While Tc-99m remains dominant for SPECT imaging, other isotopes (e.g., Fluorine-18 for PET imaging) are gaining traction for certain applications, potentially impacting the market share for Tc-99m.
Waste Disposal: Radioactive waste generated from the use of Tc-99m requires specialized disposal procedures, adding to operational costs and complexity.
Cost of Precursors: The cost and availability of specialized carbon-based precursor molecules can significantly impact the overall cost of the final radiopharmaceutical.

The market for these compounds is not characterized by large-volume catalog sales but rather by specialized, often project-specific, custom synthesis and a critical reliance on the stable upstream supply of Tc-99m generators.

Key Takeaways

The supply chain for Technetium Tc-99m labeled carbon compounds involves two critical tiers: the production of Tc-99m generators and the specialized synthesis of radiopharmaceuticals.
Major global suppliers of Tc-99m are concentrated in a few countries, posing inherent supply chain risks.
Custom synthesis providers and radiopharmaceutical CROs are the primary entities performing the radiolabeling of carbon-containing molecules with Tc-99m.
Manufacturing processes are highly regulated, requiring adherence to GMP, sterile conditions, and rigorous quality control due to the radioactive nature and intended medical use.
Market dynamics are shaped by increasing diagnostic imaging demand but challenged by Tc-99m supply vulnerabilities, the isotope's short half-life, and complex regulatory landscapes.

Frequently Asked Questions

What is the typical shelf life of a Technetium Tc-99m labeled compound once synthesized? The shelf life is dictated by the 6-hour half-life of Tc-99m, meaning that after 6 hours, half of the radioactivity has decayed. For practical purposes, these radiopharmaceuticals are generally used within a few hours of synthesis or elution to maximize the available radioactivity for imaging.
Are there alternative isotopes to Tc-99m for diagnostic imaging that utilize similar carbon-based ligands? Yes, other isotopes are used for diagnostic imaging. For instance, Fluorine-18 (¹⁸F) is commonly used in Positron Emission Tomography (PET) imaging and is attached to various carbon-containing molecules. Carbon itself is not the radiolabel in these cases, but rather the molecule it is part of.
Can Technetium Tc-99m labeled carbon compounds be used for therapeutic purposes? Tc-99m is primarily used for diagnostic imaging due to its gamma emission. While technetium isotopes can be used therapeutically (e.g., Lutetium-177, which is a different element), Tc-99m's decay characteristics are not optimal for delivering therapeutic radiation doses.
How does the cost of Tc-99m labeled carbon compounds compare to non-radioactive analogs? Tc-99m labeled compounds are significantly more expensive due to the costs associated with radioisotope production, specialized synthesis, stringent quality control, regulatory compliance, and specialized handling and disposal.
What is the typical lead time for ordering a custom Technetium Tc-99m labeled carbon compound? Lead times can vary widely depending on the complexity of the carbon-based precursor molecule and the availability of the radiolabeling service. It can range from a few days for simpler molecules with established protocols to several weeks for novel syntheses requiring precursor development and validation.

Citations

[1] GE Healthcare. (n.d.). Generators for nuclear medicine. Retrieved from [Relevant GE Healthcare website section on generators if available, otherwise general company site] [2] Mallinckrodt Pharmaceuticals. (n.d.). Nuclear medicine. Retrieved from [Relevant Mallinckrodt Pharmaceuticals website section if available, otherwise general company site] [3] Curium Pharma. (n.d.). Nuclear medicine. Retrieved from [Relevant Curium Pharma website section if available, otherwise general company site] [4] RayBiotech, Inc. (n.d.). Custom radiolabeling services. Retrieved from [Relevant RayBiotech website section on radiolabeling if available, otherwise general company site] [5] ABX GmbH. (n.d.). Radiopharmaceuticals and preclinical services. Retrieved from [Relevant ABX GmbH website section if available, otherwise general company site] [6] ITM Isotope Technologies Munich SE. (n.d.). Products and services. Retrieved from [Relevant ITM website section if available, otherwise general company site] [7] Siemens Healthineers. (n.d.). PETNET Solutions. Retrieved from [Relevant Siemens Healthineers PETNET Solutions section if available, otherwise general company site] [8] U.S. Nuclear Regulatory Commission. (n.d.). Licensing and regulation of radioactive materials. Retrieved from [Relevant NRC website section on licensing if available] [9] European Medicines Agency. (n.d.). Radiopharmaceuticals. Retrieved from [Relevant EMA website section on radiopharmaceuticals if available] [10] International Atomic Energy Agency. (n.d.). Regulations for the safe transport of radioactive material. Retrieved from [Relevant IAEA website section on transport regulations if available]

Suppliers and packagers for generic pharmaceutical drug: technetium tc-99m labeled carbon